Literature DB >> 1725554

[Comparison of the results of the treatment of patients with SSPE using various immunomodulating preparations].

W Sobczyk1, J Kulczycki, E Piłkowska, B Iwińska, D Milewska, S Szmigielski.   

Abstract

The authors analysed the results of controlled treatment by three methods of patients in the 1st or 2nd phase of SSPE in a randomized group. The groups received: I. Propionibacterium granulosum KP-45 (interferon inducer) + isoprinosine, II--TFX (thymus extract) + isoprinosine, III--only isoprinosine. In all groups the treatment was continued during 6 months. The analysis of the clinical results of these methods failed to demonstrate a statistically significant superiority of any of these methods (among others, due to small number of cases) but an evident statistical tendency was revealed suggesting a better effectiveness of combined treatment (immunostimulator + isoprinosine) in relation to treatment with isoprinosine only. The final evaluation of the results requires further observations of these patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1725554

Source DB:  PubMed          Journal:  Neurol Neurochir Pol        ISSN: 0028-3843            Impact factor:   1.621


  4 in total

1.  Subacute sclerosing panencephalitis : diagnosis and drug treatment options.

Authors:  B Anlar
Journal:  CNS Drugs       Date:  1997-02       Impact factor: 5.749

Review 2.  Subacute sclerosing panencephalitis: results of the Canadian Paediatric Surveillance Program and review of the literature.

Authors:  Craig Campbell; Simon Levin; Peter Humphreys; Wikke Walop; Renee Brannan
Journal:  BMC Pediatr       Date:  2005-12-15       Impact factor: 2.125

Review 3.  Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases.

Authors:  Jiri Sliva; Chrysoula N Pantzartzi; Martin Votava
Journal:  Adv Ther       Date:  2019-06-05       Impact factor: 3.845

Review 4.  Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course.

Authors:  Jiří Beran; Marián Špajdel; Jiří Slíva
Journal:  Viruses       Date:  2021-11-09       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.